<DOC>
	<DOCNO>NCT00343369</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . It yet know combination chemotherapy regimen effective treat acute lymphoblastic leukemia . PURPOSE : This randomized phase III trial study different combination chemotherapy regimens compare well work treat young patient acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Young Patients With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine dose daunorubicin hydrochloride equivalent 30 mg/m² doxorubicin hydrochloride pediatric patient acute lymphoblastic leukemia ( ALL ) . - Determine whether possible reduce therapy pediatric patient low-risk ALL PVA ( prednisolone-vincristine-asparaginase ) score 3+4 without loss efficacy . - Investigate role single nucleotide polymorphism infection defense gene infectious complication therapy patient . - Reduce neurological complication reduce dos intrathecal methotrexate . - Reduce allergic reaction asparaginase ( ASP ) use pegaspargase E. coli ASP . OUTLINE : This randomize , multicenter study . - Prephase : Patients randomize 1 3 treatment arm . - Arm I : Patients receive doxorubicin hydrochloride IV . - Arm II : Patients receive daunorubicin hydrochloride IV . - Arm III : Patients receive daunorubicin hydrochloride IV high dose arm II . - Induction phase : All patient receive vincristine IV 4 time weekly , daunorubicin hydrochloride IV 3 time weekly , oral prednisolone daily 4 week . - Intensive phase : Patients stratify accord risk ( low vs high ) . - Low-risk disease* : Patients receive 4 course methotrexate IV asparaginase intramuscularly ( IM ) . - High-risk disease* : Patients receive 6 course cyclophosphamide IV , methotrexate IV , asparaginase IM . All patient also receive methotrexate IV , teniposide IV , cytarabine IV , high-dose cytarabine IV , asparaginase IM completion regimen . - CNS phase : All patient receive intrathecal ( IT ) methotrexate 3 dos oral mercaptopurine 4 week . Patients T-cell acute lymphoblastic leukemia patient blast cerebrospinal fluid diagnosis whose WBC &gt; 200/nL diagnosis OR whose WBC 100-200/nL diagnosis blast &gt; 1/nL prephase chemotherapy undergo cranial irradiation . - Reinduction phase : Patients stratify accord risk ( low vs high ) - Low-risk disease* : Patients receive 2 course doxorubicin hydrochloride IV , vincristine IV , oral dexamethasone ; pegaspargase IM ; 1 course cyclophosphamide IV , cytarabine IV , oral thioguanine . - High-risk disease* : Patients receive 4 course doxorubicin hydrochloride IV , vincristine IV , oral dexamethasone ; pegaspargase IM twice ; 2 course cyclophosphamide IV , cytarabine IV , oral thioguanine . - Maintenance phase : All patient receive oral mercaptopurine daily methotrexate IV weekly 2 year diagnosis . NOTE : *In addition define Disease Characteristics , patient achieve remission induction phase treat high-risk disease , patient achieve remission induction phase treat low-risk disease PROJECTED ACCRUAL : A total 550 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Teniposide</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosed acute Bprecursor Tcell acute lymphoblastic leukemia ( ALL ) Meets 1 follow risk criterion : Lowrisk disease , define follow : WBC &lt; 25/nL Bprecursor ALL Excluding proB ALL Highrisk disease , define follow : WBC ≥ 25/nL Tcell ALL proB ALL Chromosomal translocation 4/11 PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : More 7 day since prior therapy steroid , vincristine , daunorubicin hydrochloride More 7 day since prior cytotoxic therapy</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>T-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
</DOC>